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Abstract
Background: Little is known as to how health-related quality of life (HRQoL) when measured by generic
instruments such as EQ-5D differ across smokers, ex-smokers and never-smokers in the general population;
whether the overall pattern of this difference remain consistent in each domain of HRQoL; and what implications
this variation, if any, would have for economic evaluations of tobacco control interventions.
Methods: Using the 2006 round of Health Survey for England data (n = 13,241), this paper aims to examine the
impact of smoking status on health-related quality of life in English population. Depending upon the nature of the
EQ-5D data (i.e. tariff or domains), linear or logistic regression models were fitted to control for biology, clinical
conditions, socio-economic background and lifestyle factors that an individual may have regardless of their
smoking status. Age- and gender-specific predicted values according to smoking status are offered as the potential
‘utility’ values to be used in future economic evaluation models.
Results: The observed difference of 0.1100 in EQ-5D scores between never-smokers (0.8839) and heavy-smokers
(0.7739) reduced to 0.0516 after adjusting for biological, clinical, lifestyle and socioeconomic conditions. Heavy-
smokers, when compared with never-smokers, were significantly more likely to report some/severe problems in all
five domains - mobility (67%), self-care (70%), usual activity (42%), pain/discomfort (46%) and anxiety/depression
(86%) -. ‘Utility’ values by age and gender for each category of smoking are provided to be used in the future
economic evaluations.
Conclusion: Smoking is significantly and negatively associated with health-related quality of life in English general
population and the magnitude of this association is determined by the number of cigarettes smoked. The varying
degree of this association, captured through instruments such as EQ-5D, may need to be fed into the design of
future economic evaluations where the intervention being evaluated affects (e.g. tobacco control) or is affected (e.
g. treatment for lung cancer) by individual’s (or patients’) smoking status.
Keywords: Health-related quality of life (HRQoL), EQ-5D, EuroQol, Socio-economic determinant, Economic
evaluation
Background
Smoking is an important health and economic problem.
Every year, tobacco related diseases claim the lives of
nearly six million people globally and the costs to
society of smoking are enormous [1]. Taking a very nar-
row perspective of the British National Health Service
(NHS) alone, the treatment costs of diseases that were
attributable to smoking in the year 2005/6 was £5.2 bil-
lion which is equivalent to 5.5% of the total NHS budget
for that year [2]. This figure increases several folds if we
add other indirect costs to society, e.g. lost productivity,
informal care and costs due to passive smoking. For
example, total costs attributable to smoking in Germany
in 2003 were €21.0 billion of which direct costs
amounted to only €7.5 billion (36% of total) [3]. If the
same proportion were true in the UK context, the total
costs attributable to smoking in the UK would be more
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than £14.6 billion (2005/6). The adverse effects of smok-
ing, particularly in terms of causing many preventable
diseases and premature deaths, have widely been dis-
cussed, and more recently, smoking has been a burning
issue in the debate around health inequalities as it has
been shown to have accounted for a significant propor-
tion of health inequalities [4]. Therefore, importance is
being given to several public health strategies that aim
to increase the quitting rates of current smokers as well
as regulations aiming at the prevention of health burden
due to passive smoking. Worldwide public health initia-
tives aim to prevent and reduce both the prevalence and
consequences of smoking [5]. In England alone, for
example, the average prevalence of smoking for those
aged 16 years and above has fallen from 27% [6] to 21%
in 2008 [7] since the landmark public health strategy on
tobacco control, Smoking Kills came into being in 1998
[8]. The National Institute for Health and Clinical Excel-
lence (NICE) has published a public health guidance on
smoking cessation services [9]. Despite these efforts, due
to high rates of relapse [10] and incidence of new smo-
kers, smoking remains as a major public health chal-
lenge in the years to come.
An important aspect of smoking is its association with
health-related quality of life (HRQoL). Smoking not only
kills, it affects individuals’ (current, ex- and passive smo-
kers’) quality of life too. In the UK, for example, it is
estimated that 19% of all deaths in 2002 were due to
smoking (27% in men and 11% in women) but it was
also found to be directly responsible for 12% of disability
adjusted life years lost in that year [2]. There are only a
few studies that explore the relationship between smok-
ing and health-related quality of life in the general
population. Additional file 1 summarizes these studies.
It is important to note that these studies differ widely in
the way they have measured both HRQoL and smoking
status. Nevertheless, the message appears to be consis-
tent across all studies, i.e. smokers are likely to have
worse health-related quality of life.
There is a dearth of relevant data that could be used
to inform economic evaluations of interventions that
affect (e.g. tobacco control) or are affected by population
smoking status (e.g. treatment of lung cancer). Examin-
ing the extent to which smoking is associated with
health-related quality of life may help the future studies
that look at the cost-effectiveness of interventions. For
example, limited information exists on the utility loss
due to smoking [e.g. [11]] but it is not clear whether
adjusting for other biological, clinical, lifestyle and socio-
economic conditions would lead to the same level of
utility loss, particularly in the context that a clear socio-
economic gradient exists within smoking population
[12]. The utility loss is an important input to any cost-
utility analysis. Further, the information on how utility
loss from smoking varies by age, gender and socio-eco-
nomic status could also be used as inputs to subgroup
analysis in the economic evaluation of, say smoking ces-
sation interventions. It is interesting to note from Addi-
tional file 1 that of those limited number of studies that
explored the association between HRQoL and smoking
status, only three studies used EQ-5D as a measure of
health-related quality of life. Given that EQ-5D is being
widely used in economic analyses and is the recom-
mended instrument to measure HRQoL in economic
evaluations by the National Institute for Health and
Clinical Excellence (NICE) in the UK [13], this clearly
calls for more research in this area.
In this paper, we estimate the net association of smok-
ing status on health-related quality of life, as measured
by EQ-5D, in the English general population. EQ-5D is
an instrument that captures five dimensions - mobility,
self-care, usual activities, pain/discomfort, anxiety/
depression - each of which can take one of three
responses - no problems; some or moderate problems
and extreme problems [14]. The estimated effects are
then used to predict values that can be used as ‘utilities’
attached to each smoking status in order to inform the
future economic evaluations. A secondary aim is to find
out which dimensions of HRQoL are affected by smok-
ing, and if so, to which degree they are affected.
Methods
We used the 2006 round of Health Survey for England
(HSE), available for download from the UK Data
Archive (http://www.data-archive.ac.uk). The HSE is a
series of surveys intended to monitor trends in the
nation’s health [15]. It is a representative national survey
of the population living in private households in Eng-
land in which all adults aged 16 years or older at each
household were selected for the interview. Seasonal dif-
ferences were taken into account by conducting inter-
views throughout the year. In 2006, all adults were
asked questions on cardiovascular diseases, general
health, smoking, alcohol consumption and physical
activities. The survey included adults (16 and above)
and children in the general population. This study
focuses on valid adult (16 years and above) observations
only (n = 13,241). A multi-stage stratified random sam-
pling was followed to recruit the participants whose
data was collected by using a mix of methods (face-to-
face interviews, self-completion questionnaires, and clin-
ical measurements). A detailed description of the survey
is provided elsewhere [16].
HRQoL and smoking status variables
The HSE collected data on health status by using the
EQ-5D instrument which describes health in five dimen-
sions (mobility, self-care, usual activity, pain/discomfort,
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anxiety/depression) and a single value (tariff) for each
health state can be obtained using a standardized for-
mula [15]. This type of measure is of growing relevance
in assessing public health issues [17,18] and it is one of
the most qualified and common instruments used in
population based studies on HRQoL [19]. The EQ-5D is
a widely used instrument in measuring the loss in
HRQoL by the presence of diseases caused by smoking
such as COPD [20], cancer [21] and heart diseases
[22,23].
The HSE also collected individuals’ response to ques-
tions related to smoking status. This allowed us to
assign the respondents in our sample to one of the fol-
lowing six smoking groups: never-smokers (one who has
never smoked), ex- occasional smoker (one who has
only smoked once or twice), ex-regular smoker (one
who used to smoke sometimes but never smoke a cigar-
ette now), light smoker (one who smokes under 10
cigarettes a day), moderate smoker (one who smokes
between 10-19 cigarettes a day), and heavy smokers
(one who smokes 20 or more cigarettes a day). The
advantage of this approach in smoking status compared
to two (non vs. current) or three levels (never-, ex- and
current), as widely used in the literature, is its ability to
generate more granularity in the scrutiny of how
HRQoL varies by smoking status. Results using a more
general classification of the smoking status variable are
available from the authors.
Modelling EQ-5D tariff data
As EQ-5D measure has two different types of data (i.e.
tariff or single value/mean score and dimensions), it was
important to acknowledge the nature of these data and
apply appropriate statistical methods. Both types of data
are problematic and therefore special considerations
were given as described below.
The tariff data suffers from a skewed and censored
distribution as a large proportion of the individuals have
a tariff equal to 1 (the highest possible value), has a gap
between the value of 0.883 and 1, and in some samples
may be multi-modal [24]. This indicates that alternative
models dealing with that special nature of data need to
be taken into account. Empirical evidence, largely com-
ing from the mapping exercise based on specific
patient-group samples, suggest that Tobit and censored
least absolute deviation (CLAD) estimators may be more
appropriate than ordinary least squares [25-27],
accounting for the fact that full health in terms of
HRQoL might actually exceed 1, but we do not observe
any such values in real life [28,29]. However, none of
these estimates can handle all of the above properties of
tariff data. For this reason, several studies based on
population-based data have also reported estimates from
ordinary least squares (OLS) or its variants [30,31].
Other types of models such as interval regression,
quantile regression and ordinal regression [32], are
potential candidates but in order to answer the
research questions such as the ones in this paper, they
are not very helpful. These methods require that
assumptions about cut-off points in the tariff data be
made, which although provides some interesting sta-
tistical properties to fit the models, are unrealistic and
often result in difficulty in interpreting the findings.
One of the arguments in favour of using OLS in map-
ping exercise that uses specific patient-group data is
that the upward censoring of the EQ-5D tariff at 1, as
argued in the Tobit or CLAD model, is hardly
observed in any real data [33]. However, this may not
be applicable in large population-based data such as
ours. In our sample, about 58% individuals had the
EQ-5D tariff value of 1, suggesting the OLS approach
might be inappropriate and we needed to explore
alternative approaches. Two-part models [27] dealing
with the censored part separately are difficult to inter-
pret in relation to economic evaluations. This may
also lead to further problems not broadly addressed in
the literature yet (e.g. the choice of appropriate mod-
els in two-part construct). Therefore, the focus tends
to shift towards Tobit and CLAD models which treat
the distribution of EQ-5D tariff data as censored at 1,
implying the possibility of predicting values greater
than 1 [34] and modelling a ‘latent ’ HRQoL [35].
Recent models based on experience-based and deci-
sion-utility approaches [36] or beta regression
approaches [37] are yet to be picked up by the model-
ling community.
Acknowledging that there has not been any statistical
method which can handle all the above properties of
tariff data, we tested three different models: an OLS (as
a benchmark), a Tobit (to allow for upward censoring at
1 [29]) and a CLAD (to allow for upward censoring and
heteroscedasticity [35]) to establish the association
between smoking status and the EQ-5D tariff control-
ling for other covariates. The choice of covariates was
guided by previous research in this area (see Additional
file 2). The covariates considered were: (a) biology- age,
sex, BMI, presence of cardio-vascular disease, number of
limiting conditions; (b) lifestyle - frequency of drinking,
participation in physical activity (note smoking is a
research variable and described above); (c) socioeco-
nomics - ethnicity, marital status, education, economic
status, household equivalised income, household size;
and (d) social capital - the extent to which the indivi-
dual enjoys living in their community (intuitively con-
sidered as a simple proxy for social capital). The
regression models were subject to standard diagnostic
tests, adjustment of clustering within postcode areas and
application of sampling weights.
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Modelling EQ-5D tariff in the general population (as
opposed to patient-group data) has been a challenge
and the discussions around how to model it has been
controversial in the literature [34,38]. Our own experi-
ence mirrored this problem. None of the above models
‘performed’, as they failed to pass all the diagnostic tests
carried out post-estimation. Particular problems
included normality assumptions in OLS (e.g. error terms
were not normally distributed), off-boundary predicted
values in Tobit (i.e. the mean predicted value was
greater than 1 compared to mean observed value of
0.8575), and mixed and ‘contrary-to-expectation’ signs
in CLAD (i.e. the coefficient corresponding to heavy-
smokers was positive). Therefore, we did not carry out
comparative analysis between the models; rather we
focussed on three aspects of each model - (a) the overall
F-value and significance of each covariate in the models
(all models passed this criteria); (b) the signs are as
expected a priori, e.g. HRQoL decreases with age,
increases with income and decreases with number of
longstanding illnesses (OLS performed the best in this
criterion); and (c) the ability of the model to predict
‘adjusted’ EQ-5D tariff. On this basis and as the paper
was intended to inform economic evaluations, OLS was
found to be the most useful model and therefore all
subsequent analysis on the tariff is based on OLS.
Modelling EQ-5D dimensions data
Due to the nature of dimensions data (ordinal), different
statistical approach was needed. In our sample, there
was small number of observations in the “severe pro-
blems” groups of the EQ-5D dimensions, mainly
because this is a population-based data and we would
expect a small number of people having severe pro-
blems. This did not allow us to apply ordinal regression
(or multinomial logistic regression if one rejects the
notion of ordinality in such data) as these models did
not converge or if they did, did not pass the tests for
underlying assumptions of these models, e.g. tests for
parallel lines. Therefore, in order to be meaningful and
consistent with the literature [30,39,40] the “some pro-
blems” and the “severe problems” group in each dimen-
sion were combined in order to use binary logistic
regression models with two categories: “no problems”
and “some/severe problems”. In order to be consistent,
the set of co-variates was the same as that in the models
of tariff data. The Hosmer-Lemeshow test was used to
determine that the model fit the data [41]. For interpre-
tation purposes, the odds ratios yielded by these models
are treated as relative risks, provided the event (having
problems in any dimension) is rare (< 10% of the total
sample size) and estimated odds ratios are close to 1
[42].
Assessing implications of missing data
Another complication in statistical analyses was the
missing data. There were some missing values on EQ-
5D measures (the dependent variable), smoking status
(the research variable) and others (the confounders). We
did a number of assessments to judge the implications
this would have for the findings. A total of 315 indivi-
duals out of 13,241 (2.38%) had missing EQ-5D data. In
order to establish the extent to which omitting these
315 observations from our analysis would make any dif-
ference, we modelled the probability of having a missing
EQ-5D tariff on all covariates we are interested in. The
underlying assumption was that if this probability had
not been determined significantly by any of the covari-
ates we were interested in our main analysis, excluding
these missing observations would have been reasonable.
A logistic regression was applied, and after all diagnostic
tests, it was determined that we could afford losing 315
observations from our main analysis. Thus, imputing the
values for missing data and including those in the main
analysis was not the preferred option as this would
induce another bias in the analysis. The model outputs
on the missing data analysis are not reported here but
available from the authors upon request.
We also observed a large number of missing values in
a few covariates (e.g. equivalised income -18%; BMI -
12% missing) and this needed a close scrutiny. We
chose not to impute missing data because it was difficult
to assess the nature of missingness and any attempt to
impute values was more likely to widen confidence
interval around the estimates. Instead, we opted to run
the analysis on all 12,926 observations with complete
EQ-5D but retained an additional category on each cov-
ariate (where a large number of data was missing) to
allow for the observations with missing data. For exam-
ple, we had 6 categories of income variable: 5 quintiles
of income plus a category to indicate missing data. All
analyses were performed using STATA 11.1 software.
Results
The descriptive statistics of our sample is provided in
Additional file 3. In particular, the mean EQ-5D tariff
was 0.8575 (sd = 0.2316) and the percentage of indivi-
duals who reported some or severe problems in EQ-5D
domains varied: mobility (18.1%); selfcare (5.4%); usual
activity (16.4%); pain and discomfort (32.5%); and anxi-
ety and depression (18.2%). Less than half of the sample
(47%) never smoked cigaretts, 26% were ex-regular smo-
kers, and about 22% were current smokers. About 6%
currently smoked 20 or more cigaretts a day (classified
as heavy smokers). The mean age of the sample was
48.9 years (sd = 18.3), 55.6% were females and just more
than half (55.7%) were in employment.
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Table 1 presents the observed mean value for EQ-5D
tariff and observed frequency of reporting some or
severe problems in the five EQ-5D domains by smoking
status. It is important to note that the observed value
for ‘heavy smokers’ (0.7739) is about 12 percentage
points lower than that of the never-smokers (0.8839). As
expected, the difference in tariff values between never-
smokers, ex-occasional smokers and light-smoker is not
large (0.8839 to 0.8724). A difference in those values
indicates the magnitude of decline in HRQoL in smo-
kers compared with never-smokers. Domainwise, heavy
smokers are much more likely to report a problem in all
EQ-5D domains compared to never-smokers. This ran-
ged from 49% in pain/discomfort to 149% in self-care
(p-value < .001). On the face of the observed statistics,
there is thus enough indication that smoking is signifi-
cantly associated with HRQoL, as measured by EQ-5D.
The bivariate analysis however would not tell us
whether this observed variation is the ‘net effect’ of
smoking. Table 2 provides partial results from a multi-
variate analyses that controlled for the effects of a num-
ber of variables that are expected to confound the
observed values (biology, lifestye, socioeconomics, and
social capital). As explained in the methods section, the
tariff eqation was estimated using OLS, Tobit and
CLAD estimators but all further analyses were based on
the OLS and therefore we present OLS results only. Full
OLS results are provided in Additional file 4 and other
results are available from the authors upon request. The
results indicate that there is an apparent smoking gradi-
ent in HRQoL as measured by EQ-5D, ceteris paribus.
After allowing for other covariates, the greatest effect is
observed with heavy-smokers compared to never-smo-
kers (beta of -0.0516, p-value < .005) and all forms of
smoking have negative gradients. While the unadjusted
(observed) utility loss between never-smokers and
heavy-smokers was -0.1100, the ‘net’ loss due to smok-
ing after controlling for all potential covariates was
much smaller (-0.0516) but still significant (Table 2).
As tariff is a summary measure based on the response
to the five domains, we also modelled using logistic
regression techniques the probabaility with which a pari-
cular smoking status would predict some or severe pro-
blems in each of the five domains. The last five columns
in Table 2 summarise the findings. Being a heavy-smo-
ker was associated with a 67% more likelihoold in
reporting some/severe problems in mobility ceteris pari-
bus; 70% in self-care; 42% in usual activity; 46% in pain/
Table 1 Observed values of HRQoL by smoking status (N = 13,241) in English general population
Smoking status % of N Mean* SD* Range* M** SC** UA** PD** AD**
Never smoker 46.9 .8839 .2069 -.484,1 15.04 4.19 13.66 28.20 15.26
Ex-occasional smoker 5.4 .8825 .1891 -.016,1 16.86 4.13 15.48 30.65 16.05
Ex-regular smoker 26.0 .8225 .2512 -.594,1 25.49 7.46 21.62 41.76 18.99
Light smoker 7.2 .8724 .2187 -.184,1 13.38 4.90 11.73 29.56 20.15
Moderate smoker 8.6 .8474 .2432 -.239,1 17.17 5.45 16.65 32.21 23.91
Heavy smoker 5.9 .7739 .3088 -.594,1 26.70 10.42 25.06 41.90 31.92
* Observed EQ-5D tariff
** Observed frequency (%) of “some” or “severe” problems in EQ-5D dimensions
M = Mobility; SC = Self-care; UA = Usual Activity; PD = Pain/discomfort;
AD = Anxiety/depression)
Based on Health Survey for England 2006
Table 2 The strength of association between HRQoL and smoking status (N = 12,887)
Smoking status Mean score* M** SC** UA** PD** AD**
Never smoker (Ref)
Ex-occasional smoker -.002 0.99 0.88 1.12 1.07 1.11
Ex-regular smoker -.017 1.18 1.11 1.11 1.28 1.16
Light smoker -.021 1.13 1.25 0.95 1.34 1.43
Moderate smoker -.033 1.55 1.45 1.37 1.36 1.49
Heavy smoker -.052 1.67 1.70 1.42 1.46 1.86
Correlation (predicted, observed) 0.61 0.63 0.51 0.59 0.53 0.34
R-squared (OLS)/pseudo R-squared (logistic regressions) 0.37 0.39 0.38 0.34 0.24 0.11
* Coefficient (OLS, EQ-5D tariff)
** Odds ratio (Logistic regressions, EQ-5D dimensions)
OLS = Ordinary Least Squares; M = Mobility; SC = Self-care; UA = Usual Activity;
PD = Pain/discomfort; AD = Anxiety/depression. A boldface indicates a significant p-value at < .05
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discomfort; and 86% in anxiety/depression - all values
significant at p < .005. Former smoking, in particular if
one smoked regularly in the past, was associated with
some/severe problems in mobility (OR = 1.18, p < .005),
pain/discomfort (OR = 1.28, p < .005) and anxiety/
depression (OR = 1.16, p < .005) but not with self-care
and usual activity.
The data on ‘utility’ losses because of smoking can be
very useful in cost-effectiveness modelling where the inter-
vention being evaluated affects (e.g. tobacco control) or is
affected (e.g. treatment for lung cancer) by individuals’ (or
patients’) smoking status. Table 3 presents the model pre-
dicted ‘utility’ values by age-group and gender, disaggre-
gated into all categories of smoking. As these values are
‘adjusted’ for any other potential factors including clinical
conditions, lifestyles, biology and socio-economics, the
changes in the utility values from one smoking status to
the other (e.g. from never-smoker to heavy-smoker) can
be regarded as the net change in ‘utility’ due to smoking.
To help interpret the data shown in these tables: the
mean EQ-5D tariff for a typical female from the “general
population” falling under 35-54 age band who is a
moderate smoker is 0.8716 with a standard deviation of
0.006 (first part of Table 3). A typical person in the general
population is expected to have 0.74 longstanding illnesses
(at least in our sample) and therefore these data are not
applicable in cost-effectiveness modelling for a cohort of
individuals who have no health condition. The second part
of Table 3 provides required data. The same person as
above if happens to have no longstanding illness, the utility
value will be 0.8935 with a standard deviation of 0.006.
The utility estimates reported in Table 3 can be used to
support economic evaluation of tobacco related interven-
tions/policies. The estimated utility values not only allow
calculating QALYs, but also support modelling their
uncertainty via probabilistic sensitivity analysis [43,44].
This can be done by assuming beta-distributed utility
values. The parameters of the beta-distribution can be cal-
culated based on the expected value and the standard
error reported in Table 3[43].
Discussion
This is the first study that produces a large number of
data relating to health-related quality of life (more
Table 3 Changes in adjusted ‘utility’ values (by age and gender) as the result of smoking profile*
Smoking
category
Gender 16-24 25-34 35-54 45-54 55-64 65-74 75-
100
16-24 25-34 35-54 45-54 55-64 65-74 75-
100
Never smokers Men Mean 0.9522 0.9487 0.9244 0.8775 0.8163 0.7911 0.7441 0.9665 0.9688 0.9483 0.9022 0.8455 0.8212 0.7744
SE 0.0036 0.0028 0.0025 0.0031 0.0043 0.0051 0.0052 0.0036 0.0028 0.0024 0.0031 0.0043 0.0050 0.0052
Women Mean 0.9258 0.9146 0.9038 0.8646 0.7982 0.7852 0.7102 0.9433 0.9349 0.9257 0.8907 0.8293 0.8154 0.7411
SE 0.0036 0.0027 0.0025 0.0029 0.0044 0.0048 0.0060 0.0035 0.0027 0.0025 0.0029 0.0044 0.0048 0.0060
Ex-occasional
smokers
Men Mean 0.9483 0.9431 0.9176 0.8704 0.8101 0.7868 0.7412 0.9627 0.9632 0.9414 0.8951 0.8393 0.8169 0.7715
SE 0.0073 0.0067 0.0065 0.0067 0.0074 0.0079 0.0080 0.0073 0.0068 0.0066 0.0069 0.0075 0.0080 0.0081
Women Mean 0.9225 0.9106 0.8991 0.8593 0.7930 0.7814 0.7079 0.9401 0.9309 0.9210 0.8854 0.8241 0.8116 0.7387
SE 0.0071 0.0066 0.0064 0.0065 0.0072 0.0075 0.0084 0.0071 0.0067 0.0065 0.0066 0.0074 0.0076 0.0084
Ex-regular
smokers
Men Mean 0.9342 0.9306 0.9058 0.8596 0.8020 0.7802 0.7358 0.9485 0.9507 0.9296 0.8843 0.8312 0.8103 0.7661
SE 0.0054 0.0047 0.0041 0.0042 0.0050 0.0059 0.0059 0.0053 0.0047 0.0041 0.0042 0.0050 0.0058 0.0058
Women Mean 0.9084 0.8988 0.8872 0.8479 0.7827 0.7709 0.6987 0.9260 0.9191 0.9091 0.8740 0.8138 0.8012 0.7296
SE 0.0053 0.0045 0.0041 0.0041 0.0051 0.0057 0.0067 0.0052 0.0044 0.0041 0.0041 0.0051 0.0057 0.0066
Light smokers Men Mean 0.9321 0.9266 0.9002 0.8526 0.7917 0.7684 0.7229 0.9464 0.9467 0.9241 0.8773 0.8209 0.7985 0.7532
SE 0.0060 0.0057 0.0059 0.0063 0.0071 0.0077 0.0079 0.0060 0.0058 0.0059 0.0063 0.0072 0.0076 0.0079
Women Mean 0.9063 0.8938 0.8814 0.8418 0.7748 0.7631 0.6896 0.9238 0.9141 0.9033 0.8679 0.8059 0.7934 0.7205
SE 0.0060 0.0059 0.0059 0.0062 0.0071 0.0073 0.0082 0.0060 0.0059 0.0060 0.0062 0.0071 0.0073 0.0082
Moderate
smokers
Men Mean 0.9211 0.9166 0.8899 0.8422 0.7815 0.7575 0.7112 0.9354 0.9367 0.9137 0.8669 0.8107 0.7875 0.7415
SE 0.0065 0.0062 0.0060 0.0063 0.0070 0.0079 0.0082 0.0065 0.0062 0.0061 0.0063 0.0070 0.0079 0.0082
Women Mean 0.8952 0.8835 0.8716 0.8317 0.7648 0.7520 0.6778 0.9128 0.9038 0.8935 0.8578 0.7959 0.7822 0.7087
SE 0.0065 0.0061 0.0060 0.0062 0.0070 0.0076 0.0087 0.0065 0.0061 0.0060 0.0062 0.0070 0.0076 0.0087
Heavy smokers Men Mean 0.9006 0.8971 0.8728 0.8259 0.7647 0.7395 0.6925 0.9149 0.9172 0.8967 0.8506 0.7939 0.7696 0.7228
SE 0.0093 0.0091 0.0089 0.0090 0.0095 0.0103 0.0104 0.0093 0.0091 0.0089 0.0090 0.0095 0.0103 0.0104
Women Mean 0.8742 0.8630 0.8522 0.8130 0.7466 0.7336 0.6586 0.8917 0.8833 0.8741 0.8391 0.7776 0.7638 0.6895
SE 0.0097 0.0095 0.0093 0.0093 0.0097 0.0104 0.0110 0.0097 0.0095 0.0093 0.0093 0.0098 0.0103 0.0110
*As predicted by the OLS model in the population with no limiting condition
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precisely, the ‘utility’ values) by smoking status (i.e.
extent of smoking) in English general population. Pau-
city of this kind of data has left economic evaluation
researchers very limited choice in modelling the cost-
effectiveness of interventions which affect the recipients’
smoking status (e.g. tobacco control) or are affected by
it (e.g. treatment of lung cancer). There are very few
studies that provide some estimates of utility values by
smoking status [11,33,45,46]. Our study differs from this
in several ways - our sample size is much larger, we are
able to provide granularity in estimates, and the esti-
mates reflect the ‘net’ effect of smoking controlling for
other important covariates including socioeconomics
which has been considered by some authors as having
more impact on HRQoL than smoking status itself [11].
Both the values themselves and the methods with which
such values are estimated in this paper are deemed
more robust.
Before we discuss the implications of the estimated
‘utility’ values for economic evaluations, it is important
to examine some methodological issues. First, the ‘uti-
lity’ values are based on EQ-5D mean tariff which is not
the ‘valuation’ of individual’s health state per se but a
reflection of it derived from a standard formula (extra-
polated from the original UK valuation exercise) applied
to the EQ-5D descriptive system [18]. This is a generic
problem of EQ-5D [47]. As long as EQ-5D descriptive
system remains one of the recommended tools for use
in economic evaluations [13], this issue is of less rele-
vance in the context of this paper.
The second issue relates to how best one could model
EQ-5D tariff. We used three different estimators and
found that despite the difficulty in translating the
unique features of general population tariff data under
OLS assumptions, OLS predictions were not only con-
sistent with the observed values but were also more use-
ful than those from Tobit and CLAD in terms of
measuring ‘utility loss’ across different smoking profiles.
These predictions could be valuable inputs to estimate
QALYs in economic evaluation of different interven-
tions, including tobacco control policies. In addition, the
literature suggests that Tobit and CLAD estimations,
although may perform well in specific patient-group
data, do differ from the OLS in general population and
are biased [34,35]. Note however that many earlier stu-
dies, mostly based on patient group data as opposed to
population data as in our case, have resorted to OLS or
its variants [25,30] and therefore it is not unreasonable
to present predictions based on OLS estimator.
Although there have been some very recent efforts to
look at alternative ways in which health utility data
could be modelled [24,36,37,48] which is yet to be scru-
tinized closely by modelling community, we emphasize
that future research continues to propose and debate
estimation strategies that would take into account all
the unique features of EQ-5D tariff data.
The third issue is the nature of the utility values. Our
results are based on the general population as opposed
to patient group and therefore the utility values are that
of the general population, and not that of the specific
patient population. This may have implications for eco-
nomic modelling based on a cohort with specific disease
conditions. However, it is important to note that the
methods with which these values are derived reflect the
net losses in utilities due to the degree of smoking. That
is, these losses have already been adjusted for one’s biol-
ogy, clinical conditions, lifestyles and socioeconomics
(see Additional file 4 for the impact of limiting condi-
tions). It is then up to the economic modeller to decide
appropriate states in the Markov model that allows the
use of such data in a specific patient group.
There are a number of implications of our findings.
The most resounding conclusion that can be drawn
from this study is that smoking is significantly asso-
ciated with HRQoL in English general population. This
is consistent with studies reported from similar high-
income, industrialized countries such as Spain [49], Fin-
land [50], Australia [51], the Netherlands [52], USA
[46,53], Denmark [54], and also with earlier UK studies
[11,45,55]. In quantitative terms, moving from never-
smoking to heavy-smoking profile leads to a utility loss
of 0.0516. Likewise, supporting heavy-smokers to quit
by various support mechanisms will lead to a utility gain
of 0.0347. When applied at the population level, these
small gains could translate into significant economic
returns as explained below.
Our findings suggest that the more frequently one
smokes, the worse quality of life they could expect from
their smoking habit- regardless of other biological, clini-
cal, lifestyle and socioeconomics. The absolute difference
of 0.0347 in EQ-5D tariff between current heavy-smo-
kers and ex-regular smoker is remarkable. Putting this
into perspectives, there are currently 10 million smokers
in England [56] of which according to our own data
27% (2.7 million) can be classified as heavy-smokers.
Assuming that 6.4% of these smokers would receive a
nicotine replacement therapy (NRT) prescription [57],
16% of whom will successfully quit at the end of the
year [10], and conservatively assuming no deaths occur-
ring in this group in this one year, this smoking cessa-
tion alone would save about 1000 QALYs at the end of
the first year. If the NICE threshold for a QALY is used
to value these benefits, NRT prescription alone could
potentially save between £20-30 million (minus the
costs of NRT provision) in one year.
Using the data provided in Table 3, a number of such
policy simulations can be performed. Furthermore, these
data can inform more robust economic evaluations of
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interventions that affect population smoking status (e.g.
tobacco control) or are affected by it (e.g. lung cancer
treatment). In particular, the information in the changes
in utility due to smoking status in the population group
that has no longstanding illness is valuable. By providing
the utility values by age and gender, our estimates pro-
vides much more flexibility for cost-effectiveness
researchers to model QALYs, compared to, for instance,
the Scottish study [11] which provide a single estimate:
the difference in ex-smokers and smokers (-0.0347)
only. Our values are robust in the sense that they repre-
sent the net utility loss due to smoking. The standard
deviation attached to each estimate will allow the mod-
ellers enough room to assess the uncertainty around
their QALYs figures.
Finally, although the main driver of the paper is to
provide utility values to inform the future economic eva-
luations, the findings around the EQ-5D domains war-
rant some interesting discussions. The fact that the
frequency of severe conditions in our sample in all five
domains was less than 4% mirrors the concern that EQ-
5D is less able to pick up severe conditions [47]. Thus,
combining ‘some’ and ‘severe’ problems into one cate-
gory to model the effect that smoking status has on
each of the five domains is not unreasonable. The find-
ings that the degree of smoking, particularly more than
20 or more cigarettes a day, affects all domains is con-
sistent with a priori expectations but what is new is the
quantification of differential effect this has on the
domains.
The fact that being a heavy-smoker is associated with
86% more likelihood of reporting some/severe problems
in anxiety/depression compared with 42% in usual activ-
ity, coupled with the finding that quitting smoking (e.g.
in the case of ex-regular smokers) does not affect self-
care and usual activity but it continues to affect the
other three domains, has two immediate implications
for cessation interventions: (a) in order to improve qual-
ity of life among quitters, cessation services may need to
combine other forms of support, e.g. facilitate access to
mental health services; and (b) anxiety/depression and
mobility are the two domains on which cessation ser-
vices can have the greatest impact. Putting this into per-
spectives, encouraging heavy-smokers quit by various
support mechanisms will lead to a massive 70% reduc-
tion in them reporting some/severe problems in anxiety/
depression (49% in mobility). This is an important
aspect to be communicated as an individual benefit of
smokers in quitting campaigns. This is also supported
by studies on the basic association of nicotine and anxi-
ety/depression [58,59]. However, in order to assure sus-
tained abstinence, it may be necessary to address/
monitor mental health of those who attempt to quit
right at the time of the intervention and beyond.
Conclusion
Smoking is significantly and negatively associated with
HRQoL in English general population. While the
observed difference in EQ-5D mean score between
individuals who never smoked and those who smoke at
least 20 cigarettes a day is about 0.10, the actual differ-
ence after controlling for other biological, clinical, life-
styles and socioeconomic conditions is smaller (0.05)
but is still significant. The implication is that support-
ing smokers quit will improve the population QALYs.
The varying degree of the association between smoking
profile and HRQoL need to be fed into the design of
future economic evaluations where the intervention
being evaluated affects (e.g. tobacco control) or is
affected (e.g. treatment for lung cancer) by individuals’
(or patients’) smoking status. The net utility loss data
due to various smoking profile reported in this paper
is rich and can inform robust economic evaluations in
the future.
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